Drug Profile
Research programme: plasma protein therapeutics - CSL
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CSL
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
- 16 Apr 2010 Early research in Undefined indication in Australia (unspecified route)